A Prospective Registry Study to Assess Real-world Patient Characteristics, Treatment Patterns, and Longitudinal Outcomes in Patients Receiving Mavacamten and Other Treatments for Symptomatic Obstructive Hypertrophic Cardiomyopathy (Obstructive-HCM) (DISCOVER-HCM)
Deliver Insights in Hypertrophic Cardiomyopathy and Observational Outcomes in Real World: United States and European Prospective Registry Study
Sponsor: Bristol-Myers Squibb
Listed as NCT05489705, this observational or N/A phase trial focuses on Obstructive Hypertrophic Cardiomyopathy and remains actively recruiting participants. Sponsored by Bristol-Myers Squibb, it has been updated 18 times since 2022, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
18 versions recorded-
Dec 2025 — Present [monthly]
Recruiting
-
Sep 2025 — Dec 2025 [monthly]
Recruiting
-
May 2025 — Sep 2025 [monthly]
Recruiting
-
Jan 2025 — May 2025 [monthly]
Recruiting
-
Oct 2024 — Jan 2025 [monthly]
Recruiting
▶ Show 13 earlier versions
-
Sep 2024 — Oct 2024 [monthly]
Recruiting
-
Aug 2024 — Sep 2024 [monthly]
Recruiting
-
Jul 2024 — Aug 2024 [monthly]
Recruiting
-
May 2024 — Jul 2024 [monthly]
Recruiting
-
Mar 2024 — May 2024 [monthly]
Recruiting
-
Feb 2024 — Mar 2024 [monthly]
Recruiting
-
Jan 2024 — Feb 2024 [monthly]
Recruiting
-
Dec 2023 — Jan 2024 [monthly]
Recruiting
-
Nov 2023 — Dec 2023 [monthly]
Recruiting
-
Oct 2023 — Nov 2023 [monthly]
Recruiting
-
Mar 2023 — Oct 2023 [monthly]
Recruiting
-
Nov 2022 — Mar 2023 [monthly]
Recruiting
Status: Not Yet Recruiting → Recruiting
-
Sep 2022 — Nov 2022 [monthly]
Not Yet Recruiting
First recorded
Aug 2022
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Bristol-Myers Squibb
For direct contact, visit the study record on ClinicalTrials.gov .